Cebsulfase alfa is a Recombinant Enzyme owned by Takeda Pharmaceutical, and is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing.
Cebsulfase alfa (TAK-611, SHP-611, HGT-1110, recombinant human arylsulfatase A) is enzyme replacement therapy to promote the arylsulfatase A enzyme levels. Arylsulfatase A is required for the breakdown of sulfatides, also called glycolipid- cerebroside sulfates, which are fats present in myelin. HGT-1110 when directly delivered to central nervous system, arylsulfatase A is taken by brain cells resulting in a reduction of sulfatide storage in the central nervous system. HGT-1110 depletes the accumulated sulfatide level and prevents the disruption of the myelin structure. It protects neurons from causing demyelination in the central nervous system.
The revenue for Cebsulfase alfa is expected to reach a total of $1.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cebsulfase alfa NPV Report.
Cebsulfase alfa Overview
Cebsulfase alfa (TAK-611,SHP-611, HGT-1110, recombinant human arylsulfatase A) is under development for the treatment of metachromatic leukodystrophy (MLD). HGT-1110 is an intrathecal enzyme replacement therapy (ERT) which is administered via an intrathecal drug delivery device (IDDD). It is an arylsulfatase A formulation derived from human cells and is compatible for direct CNS delivery.
Takeda Pharmaceutical Overview
Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.
Quick View – Cebsulfase alfa
|Highest Development Stage|